{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:08:16Z","timestamp":1784920096861,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glycosylation is an integral part in health and disease, as emphasized by the growing number of identified glycosylation defects. In humans, proteins are modified with a diverse range of glycoforms synthesized in complex biosynthetic pathways. Glycosylation disorders have been described in congenital disorders of glycosylation (CDG) as well as in acquired disease conditions such and non-alcoholic fatty liver disease (NAFLD). A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans. Using an optimized method protocol, we determined the glycosylation site occupancy from four proteins of hepatic and lymphatic origin from CDG and NAFLD patients. We found variable degrees of site occupancy, depending on the tissue of origin and the disease condition. In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels. In NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying for its use as a potential biomarker. Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date. Our findings suggest the use of serum protein hyperglycosylation as a biomarker for early stages of NAFLD.<\/jats:p>","DOI":"10.1038\/srep33927","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T08:59:32Z","timestamp":1476176372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Glycosylation site occupancy in health, congenital disorder of glycosylation and fatty liver disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Andreas J.","family":"H\u00fclsmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Tobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricie","family":"Burda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Hennet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"key":"BFsrep33927_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.yexmp.2014.09.005","volume":"97","author":"MG Neuman","year":"2014","unstructured":"Neuman, M. G. et al. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol 97, 492\u2013510, doi: 10.1016\/j.yexmp.2014.09.005 (2014).","journal-title":"Exp Mol Pathol"},{"key":"BFsrep33927_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrgastro.2011.134","volume":"8","author":"J Altamirano","year":"2011","unstructured":"Altamirano, J. & Bataller, R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 8, 491\u2013501, doi: 10.1038\/nrgastro.2011.134 (2011).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"BFsrep33927_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519\u20131523, doi: 10.1126\/science.1204265 (2011).","journal-title":"Science"},{"key":"BFsrep33927_CR4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","volume":"149","author":"R Loomba","year":"2015","unstructured":"Loomba, R. et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology 149, 1784\u20131793, doi: 10.1053\/j.gastro.2015.08.011 (2015).","journal-title":"Gastroenterology"},{"key":"BFsrep33927_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","volume":"47","author":"A Lonardo","year":"2015","unstructured":"Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. & Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47, 181\u2013190, doi: 10.1016\/j.dld.2014.09.020 (2015).","journal-title":"Dig Liver Dis"},{"key":"BFsrep33927_CR6","doi-asserted-by":"publisher","first-page":"10851","DOI":"10.3748\/wjg.v20.i31.10851","volume":"20","author":"E Fitzpatrick","year":"2014","unstructured":"Fitzpatrick, E. & Dhawan, A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 20, 10851\u201310863, doi: 10.3748\/wjg.v20.i31.10851 (2014).","journal-title":"World J Gastroenterol"},{"key":"BFsrep33927_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.mayocp.2015.06.013","volume":"90","author":"EK Spengler","year":"2015","unstructured":"Spengler, E. K. & Loomba, R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 90, 1233\u20131246, doi: 10.1016\/j.mayocp.2015.06.013 (2015).","journal-title":"Mayo Clin Proc"},{"key":"BFsrep33927_CR8","doi-asserted-by":"publisher","first-page":"236S","DOI":"10.1097\/01.alc.0000190659.85025.b3","volume":"29","author":"T Ohtsuka","year":"2005","unstructured":"Ohtsuka, T., Tsutsumi, M., Fukumura, A., Tsuchishima, M. & Takase, S. Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. Alcohol Clin Exp Res 29, 236S\u2013239S (2005).","journal-title":"Alcohol Clin Exp Res"},{"key":"BFsrep33927_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm1006","volume":"10","author":"N Callewaert","year":"2004","unstructured":"Callewaert, N. et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10, 429\u2013434 (2004).","journal-title":"Nat Med"},{"key":"BFsrep33927_CR10","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep.21855","volume":"46","author":"XE Liu","year":"2007","unstructured":"Liu, X. E. et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46, 1426\u20131435, doi: 10.1002\/hep.21855 (2007).","journal-title":"Hepatology"},{"key":"BFsrep33927_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.dld.2011.10.015","volume":"44","author":"B Blomme","year":"2012","unstructured":"Blomme, B. et al. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis 44, 315\u2013322, doi: 10.1016\/j.dld.2011.10.015 (2012).","journal-title":"Dig Liver Dis"},{"key":"BFsrep33927_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1021\/pr800656e","volume":"8","author":"C Chen","year":"2009","unstructured":"Chen, C. et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res 8, 463\u2013470, doi: 10.1021\/pr800656e (2009).","journal-title":"J Proteome Res"},{"key":"BFsrep33927_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.bbadis.2009.08.005","volume":"1792","author":"J Jaeken","year":"2009","unstructured":"Jaeken, J., Hennet, T., Matthijs, G. & Freeze, H. H. CDG nomenclature: time for a change! Biochimica et biophysica acta 1792, 825\u2013826, doi: 10.1016\/j.bbadis.2009.08.005 (2009).","journal-title":"Biochimica et biophysica acta"},{"key":"BFsrep33927_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/clinchem\/47.1.13","volume":"47","author":"T Arndt","year":"2001","unstructured":"Arndt, T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clinical chemistry 47, 13\u201327 (2001).","journal-title":"Clinical chemistry"},{"key":"BFsrep33927_CR15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/clinchem\/40.11.2078","volume":"40","author":"P Bean","year":"1994","unstructured":"Bean, P. & Peter, J. B. Allelic D variants of transferrin in evaluation of alcohol abuse: differential diagnosis by isoelectric focusing-immunoblotting-laser densitometry. Clinical chemistry 40, 2078\u20132083 (1994).","journal-title":"Clinical chemistry"},{"key":"BFsrep33927_CR16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1373\/clinchem.2003.029629","volume":"50","author":"A Helander","year":"2004","unstructured":"Helander, A., Bergstrom, J. & Freeze, H. H. Testing for congenital disorders of glycosylation by HPLC measurement of serum transferrin glycoforms. Clinical chemistry 50, 954\u2013958, doi: 10.1373\/clinchem.2003.029629 (2004).","journal-title":"Clinical chemistry"},{"key":"BFsrep33927_CR17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/clinchem\/47.3.513","volume":"47","author":"JM Lacey","year":"2001","unstructured":"Lacey, J. M., Bergen, H. R., Magera, M. J., Naylor, S. & O\u2019Brien, J. F. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clinical chemistry 47, 513\u2013518 (2001).","journal-title":"Clinical chemistry"},{"key":"BFsrep33927_CR18","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1074\/mcp.M700361-MCP200","volume":"6","author":"AJ H\u00fclsmeier","year":"2007","unstructured":"H\u00fclsmeier, A. J., Paesold-Burda, P. & Hennet, T. N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol Cell Proteomics 6, 2132\u20132138, doi: 10.1074\/mcp.M700361-MCP200 (2007).","journal-title":"Mol Cell Proteomics"},{"key":"BFsrep33927_CR19","doi-asserted-by":"crossref","unstructured":"Plomp, R., Bondt, A., de Haan, N., Rombouts, Y. & Wuhrer, M. Recent advances in clinical glycoproteomics of immunoglobulins. Mol Cell Proteomics, doi: 10.1074\/mcp.O116.058503 (2016).","DOI":"10.1074\/mcp.O116.058503"},{"key":"BFsrep33927_CR20","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s10875-010-9405-6","volume":"30","author":"RM Anthony","year":"2010","unstructured":"Anthony, R. M. & Ravetch, J. V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. Journal of clinical immunology 30 Suppl 1, S9\u201314, doi: 10.1007\/s10875-010-9405-6 (2010).","journal-title":"Journal of clinical immunology"},{"issue":"11","key":"BFsrep33927_CR21","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/ejhg.2015.25","volume":"23","author":"Shili Lin","year":"2015","unstructured":"Maratha, A. et al. Classical galactosaemia: novel insights in IgG N-glycosylation and N-glycan biosynthesis. Eur J Hum Genet, doi: 10.1038\/ejhg.2015.254 (2016).","journal-title":"European Journal of Human Genetics"},{"key":"BFsrep33927_CR22","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1021\/acs.jproteome.5b00709","volume":"14","author":"R Saldova","year":"2015","unstructured":"Saldova, R. et al. N-Glycosylation of Serum IgG and Total Glycoproteins in MAN1B1 Deficiency. J Proteome Res 14, 4402\u20134412, doi: 10.1021\/acs.jproteome.5b00709 (2015).","journal-title":"J Proteome Res"},{"key":"BFsrep33927_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","volume":"25","author":"JN Arnold","year":"2007","unstructured":"Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25, 21\u201350, doi: 10.1146\/annurev.immunol.25.022106.141702 (2007).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep33927_CR24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4049\/jimmunol.1502136","volume":"196","author":"FS van de Bovenkamp","year":"2016","unstructured":"van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T. & Rombouts, Y. The Emerging Importance of IgG Fab Glycosylation in Immunity. J Immunol 196, 1435\u20131441, doi: 10.4049\/jimmunol.1502136 (2016).","journal-title":"J Immunol"},{"key":"BFsrep33927_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1172\/JCI33189","volume":"118","author":"H Suzuki","year":"2008","unstructured":"Suzuki, H. et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118, 629\u2013639, doi: 10.1172\/JCI33189 (2008).","journal-title":"J Clin Invest"},{"key":"BFsrep33927_CR26","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1021\/pr500146y","volume":"13","author":"C McCarthy","year":"2014","unstructured":"McCarthy, C. et al. The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res 13, 3131\u20133143, doi: 10.1021\/pr500146y (2014).","journal-title":"J Proteome Res"},{"key":"BFsrep33927_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1749-6632.2011.06420.x","volume":"1253","author":"E Dempsey","year":"2012","unstructured":"Dempsey, E. & Rudd, P. M. Acute phase glycoproteins: bystanders or participants in carcinogenesis? Ann N Y Acad Sci 1253, 122\u2013132, doi: 10.1111\/j.1749-6632.2011.06420.x (2012).","journal-title":"Ann N Y Acad Sci"},{"key":"BFsrep33927_CR28","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/clinchem\/37.12.2029","volume":"37","author":"H Stibler","year":"1991","unstructured":"Stibler, H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clinical chemistry 37, 2029\u20132037 (1991).","journal-title":"Clinical chemistry"},{"key":"BFsrep33927_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0304-4165(97)00135-9","volume":"1380","author":"J Peter","year":"1998","unstructured":"Peter, J. et al. Identification of carbohydrate deficient transferrin forms by MALDI-TOF mass spectrometry and lectin ELISABiochim Biophys Acta 1998 Aug 24;1381(3):356. Biochimica et biophysica acta 1380, 93\u2013101 (1998).","journal-title":"Biochimica et biophysica acta"},{"key":"BFsrep33927_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1086\/318199","volume":"68","author":"S Gr\u00fcnewald","year":"2001","unstructured":"Gr\u00fcnewald, S., Schollen, E., Van Schaftingen, E., Jaeken, J. & Matthijs, G. High residual activity of PMM2 in patients\u2019 fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am J Hum Genet 68, 347\u2013354, doi: 10.1086\/318199 (2001).","journal-title":"Am J Hum Genet"},{"key":"BFsrep33927_CR31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321, doi: 10.1002\/hep.20701 (2005).","journal-title":"Hepatology"},{"key":"BFsrep33927_CR32","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1021\/acs.jproteome.5b00756","volume":"14","author":"Q Hong","year":"2015","unstructured":"Hong, Q. et al. A Method for Comprehensive Glycosite-Mapping and Direct Quantitation of Serum Glycoproteins. J Proteome Res 14, 5179\u20135192, doi: 10.1021\/acs.jproteome.5b00756 (2015).","journal-title":"J Proteome Res"},{"key":"BFsrep33927_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.febslet.2004.08.061","volume":"576","author":"Y Satomi","year":"2004","unstructured":"Satomi, Y., Shimonishi, Y. & Takao, T. N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. FEBS letters 576, 51\u201356, doi: 10.1016\/j.febslet.2004.08.061 (2004).","journal-title":"FEBS letters"},{"key":"BFsrep33927_CR34","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0021-9258(19)76994-4","volume":"246","author":"AG Morell","year":"1971","unstructured":"Morell, A. G., Gregoriadis, G., Scheinberg, I. H., Hickman, J. & Ashwell, G. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246, 1461\u20131467 (1971).","journal-title":"J Biol Chem"},{"key":"BFsrep33927_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/glycob\/cwl057","volume":"17","author":"Y Kanda","year":"2007","unstructured":"Kanda, Y. et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17, 104\u2013118, doi: 10.1093\/glycob\/cwl057 (2007).","journal-title":"Glycobiology"},{"key":"BFsrep33927_CR36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.4161\/mabs.3.6.17922","volume":"3","author":"K Zheng","year":"2011","unstructured":"Zheng, K., Bantog, C. & Bayer, R. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 3, 568\u2013576, doi: 10.4161\/mabs.3.6.17922 (2011).","journal-title":"mAbs"},{"key":"BFsrep33927_CR37","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/glycob\/10.12.1277","volume":"10","author":"T Dupre","year":"2000","unstructured":"Dupre, T. et al. Defect in N-glycosylation of proteins is tissue-dependent in congenital disorders of glycosylation Ia. Glycobiology 10, 1277\u20131281 (2000).","journal-title":"Glycobiology"},{"key":"BFsrep33927_CR38","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1074\/mcp.M112.023259","volume":"12","author":"P Pompach","year":"2013","unstructured":"Pompach, P. et al. Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol Cell Proteomics 12, 1281\u20131293, doi: 10.1074\/mcp.M112.023259 (2013).","journal-title":"Mol Cell Proteomics"},{"key":"BFsrep33927_CR39","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1021\/pr500128t","volume":"13","author":"J Zhu","year":"2014","unstructured":"Zhu, J. et al. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res 13, 2986\u20132997, doi: 10.1021\/pr500128t (2014).","journal-title":"J Proteome Res"},{"key":"BFsrep33927_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/hep.510270121","volume":"27","author":"MD Weltman","year":"1998","unstructured":"Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M. & Liddle, C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128\u2013133, doi: 10.1002\/hep.510270121 (1998).","journal-title":"Hepatology"},{"key":"BFsrep33927_CR41","doi-asserted-by":"publisher","first-page":"e66328","DOI":"10.1371\/journal.pone.0066328","volume":"8","author":"Y Kamada","year":"2013","unstructured":"Kamada, Y. et al. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One 8, e66328, doi: 10.1371\/journal.pone.0066328 (2013).","journal-title":"PLoS One"},{"key":"BFsrep33927_CR42","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/hep.28002","volume":"62","author":"Y Kamada","year":"2015","unstructured":"Kamada, Y. et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology 62, 1433\u20131443, doi: 10.1002\/hep.28002 (2015).","journal-title":"Hepatology"},{"key":"BFsrep33927_CR43","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966\u2013968, doi: 10.1093\/bioinformatics\/btq054 (2010).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep33927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33927","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:15:16Z","timestamp":1672899316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep33927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,31]]}},"alternative-id":["BFsrep33927"],"URL":"https:\/\/doi.org\/10.1038\/srep33927","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]},"assertion":[{"value":"12 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33927"}}